- Email: [email protected]
P080 Our experience in treatment of the first patient who came down with the Burkitts lymphoma and AIDS in BiH
S100
Poster Sessions
P080 Our experience in treatment of the first patient who came down with the Burkitts lymphoma and AIDS in BiH A. Dizdarevic, V. Hadziosman, J. Toplovic, A. Sofo, M. Vila. Hospital Center, Sarajevo, Bosnia and Hercegovina Therapy for ARL-Burkitt’s lymphoma is big problem,because the application of schock chemoth. regimens is considerably limited in case of the previously immune compromised patients. A great number of intensive therapeutic regimes shall be considered in future in connection with the patients suffering from Burkitt’s lymphoma and AIDS which considerably prolonged the survival and remisson of disease Aim: We have found the NHL with 3% of the HIV+ patients which represent a considerably higher incidence than it is the case with the patients suffering from the HIV+ who came down with the NHL. As for the ARL, highly aggressive lymphoma of Burkitt’s lymphoma is reacting mainly badly to the standard chemotherapy regimewhiletheintensive chemotherapy protocols are showing a highly progressive improvement. Patients and methods: In April 2005, at the Clinic of Infectology, a male at the age of 31 was diagnosed the Burkitt’s lymphoma CSIIB (bulky disease) - the AIDS diagnosis was made four month earlier. The laboratory tests detected a regular blood test, an increased LDH level, a positive serology for EBV, HIV control Elisa test and the PCR negative, CD4 of peripheral blood value 90 blood cells/cm3 . There were not any lymph cells found during the needle biopsy of the bone marrow and liquor. The patient received 8 cycles of the above CHOP with i.t. MTX, G-CSF, trimetroprimsulfa, fluconasol, HAART andirradiation. Disease in relapse was manifested in the abdomen and retroperitoenuma lympadenopathy with lymph liver and spleen infiltrates and CNS. This is when an intensive chemoth, protocol CODOX (metotrexat of 1,5gr/m2 ) with i.t. therapy (MTX, AraC, Dexa), HAART, G-CSF-antimicrobial prophylaxis therapy and blood derivates. Results: The remission of disease lasting for about less than three month was achieved by the above chemotherapy CHOP and raditherapy.All the above was without febrile attacks with the post-irradiation mucositis of gradus II.After CODOX the improvement of the neurological excesses along with the objective regression of the abdomen and retroperitoneal lymph infiltrate in the “second therapy line” were achieved as well as survival of the patient for term of five months. Conclusion: The treatment of our first patient suffering from the Burkitt’s lymphoma and AIDS with the intensive chemotherapy CODOX regime along with a HAART therapy and G-CSF did not achieve any considerate or intensive side effects in the, but it showed to be more efficient compared to the standard CHOP protocol.
P081 Spontaneous splenic rupture in two patients with hematologic malignancy T. Szotkowski, R. Szotkowska, Z. Pikalova, T. Tichy, P. Flodr, M. Tichy, D. Houserkova, V. Benysek, N. Zlamalova, V. Ruzicka, K. Indrák. Department of Hemato-Oncology, Faculty Hospital, Olomouc, Czech Republic Introduction: Spontaneous splenic rupture (SSR) is a very rare complication described in several hundred patients, mainly as case reports. It is defined as a splenic rupture without antecedent injury. The authors of the present paper describe the only two SSR cases diagnosed at the Hematooncology department, coincidentally in one year. Patients: The first patient was admitted to hospital because of planned chemotherapy for relapsed hairy cell leukemia. The second was directed to the Hemato-oncology outpatient department because of anemia and painful splenomegaly diagnosed by a physician. The diagnose of hematologic malignancy (diffuse large B-cell lymphoma) was determined subsequently on the basis of histological examination of the spleen. Conclusion: It is necessary to consider SSR not only in patients with known diagnosis of malignant disease but in the patients with negative anamnesis, too. The aim of the paper is to draw attention to the existence of this complication.
Stem cell transplantation I P082 Enhancement of immune and hematopoietic reconstitution by IL-7 following experimental bone marrow transplantation in a murine model may be mediated by IL-2 and RAG-1 activation A. Abdul-Hai, A. Ben-Yehuda, G. Friedman, D. Ergaz. Department of Bone Marrow Transplantation, Hadassah-Hebrew University Medical Center, Jerusalem, Israel Interleukin-7 (IL-7) is a crucial cytokine that is involved in the early development of B and T cells. In order to study the role of IL-7 on thymopoiesis and peripheral T cell expansion and on reconstitution from uncommitted stem cells in the setting of allogeneic transplantation. Aim: We studied the efficacy of recombinant human IL-7 (rIL-7) on in vitro incubated murine bone marrow cells (BMC), in a model of murine syngeneic bone marrow transplantation (BMT). Patients and methods: BM cells from BALB/c mice cultured with either rIL-7 or rIL-2 or combination of both for 2 days were injected to recipient animals (IV 107 nucleated cells) one day after total body irradiation of 800 cGy. Animals were then divided into several groups. One group was transplanted with rIL-7 incubated nuclear cells and received in vivo rIL-7
Poster Sessions
P080 Our experience in treatment of the first patient who came down with the Burkitts lymphoma and AIDS in BiH A. Dizdarevic, V. Hadziosman, J. Toplovic, A. Sofo, M. Vila. Hospital Center, Sarajevo, Bosnia and Hercegovina Therapy for ARL-Burkitt’s lymphoma is big problem,because the application of schock chemoth. regimens is considerably limited in case of the previously immune compromised patients. A great number of intensive therapeutic regimes shall be considered in future in connection with the patients suffering from Burkitt’s lymphoma and AIDS which considerably prolonged the survival and remisson of disease Aim: We have found the NHL with 3% of the HIV+ patients which represent a considerably higher incidence than it is the case with the patients suffering from the HIV+ who came down with the NHL. As for the ARL, highly aggressive lymphoma of Burkitt’s lymphoma is reacting mainly badly to the standard chemotherapy regimewhiletheintensive chemotherapy protocols are showing a highly progressive improvement. Patients and methods: In April 2005, at the Clinic of Infectology, a male at the age of 31 was diagnosed the Burkitt’s lymphoma CSIIB (bulky disease) - the AIDS diagnosis was made four month earlier. The laboratory tests detected a regular blood test, an increased LDH level, a positive serology for EBV, HIV control Elisa test and the PCR negative, CD4 of peripheral blood value 90 blood cells/cm3 . There were not any lymph cells found during the needle biopsy of the bone marrow and liquor. The patient received 8 cycles of the above CHOP with i.t. MTX, G-CSF, trimetroprimsulfa, fluconasol, HAART andirradiation. Disease in relapse was manifested in the abdomen and retroperitoenuma lympadenopathy with lymph liver and spleen infiltrates and CNS. This is when an intensive chemoth, protocol CODOX (metotrexat of 1,5gr/m2 ) with i.t. therapy (MTX, AraC, Dexa), HAART, G-CSF-antimicrobial prophylaxis therapy and blood derivates. Results: The remission of disease lasting for about less than three month was achieved by the above chemotherapy CHOP and raditherapy.All the above was without febrile attacks with the post-irradiation mucositis of gradus II.After CODOX the improvement of the neurological excesses along with the objective regression of the abdomen and retroperitoneal lymph infiltrate in the “second therapy line” were achieved as well as survival of the patient for term of five months. Conclusion: The treatment of our first patient suffering from the Burkitt’s lymphoma and AIDS with the intensive chemotherapy CODOX regime along with a HAART therapy and G-CSF did not achieve any considerate or intensive side effects in the, but it showed to be more efficient compared to the standard CHOP protocol.
P081 Spontaneous splenic rupture in two patients with hematologic malignancy T. Szotkowski, R. Szotkowska, Z. Pikalova, T. Tichy, P. Flodr, M. Tichy, D. Houserkova, V. Benysek, N. Zlamalova, V. Ruzicka, K. Indrák. Department of Hemato-Oncology, Faculty Hospital, Olomouc, Czech Republic Introduction: Spontaneous splenic rupture (SSR) is a very rare complication described in several hundred patients, mainly as case reports. It is defined as a splenic rupture without antecedent injury. The authors of the present paper describe the only two SSR cases diagnosed at the Hematooncology department, coincidentally in one year. Patients: The first patient was admitted to hospital because of planned chemotherapy for relapsed hairy cell leukemia. The second was directed to the Hemato-oncology outpatient department because of anemia and painful splenomegaly diagnosed by a physician. The diagnose of hematologic malignancy (diffuse large B-cell lymphoma) was determined subsequently on the basis of histological examination of the spleen. Conclusion: It is necessary to consider SSR not only in patients with known diagnosis of malignant disease but in the patients with negative anamnesis, too. The aim of the paper is to draw attention to the existence of this complication.
Stem cell transplantation I P082 Enhancement of immune and hematopoietic reconstitution by IL-7 following experimental bone marrow transplantation in a murine model may be mediated by IL-2 and RAG-1 activation A. Abdul-Hai, A. Ben-Yehuda, G. Friedman, D. Ergaz. Department of Bone Marrow Transplantation, Hadassah-Hebrew University Medical Center, Jerusalem, Israel Interleukin-7 (IL-7) is a crucial cytokine that is involved in the early development of B and T cells. In order to study the role of IL-7 on thymopoiesis and peripheral T cell expansion and on reconstitution from uncommitted stem cells in the setting of allogeneic transplantation. Aim: We studied the efficacy of recombinant human IL-7 (rIL-7) on in vitro incubated murine bone marrow cells (BMC), in a model of murine syngeneic bone marrow transplantation (BMT). Patients and methods: BM cells from BALB/c mice cultured with either rIL-7 or rIL-2 or combination of both for 2 days were injected to recipient animals (IV 107 nucleated cells) one day after total body irradiation of 800 cGy. Animals were then divided into several groups. One group was transplanted with rIL-7 incubated nuclear cells and received in vivo rIL-7